PDT Partners LLC Acquires 63,804 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

PDT Partners LLC boosted its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 37.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 235,097 shares of the biopharmaceutical company's stock after buying an additional 63,804 shares during the period. PDT Partners LLC owned approximately 0.38% of Sage Therapeutics worth $1,277,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in SAGE. Picton Mahoney Asset Management raised its holdings in shares of Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Sage Therapeutics in the fourth quarter worth approximately $49,000. Ieq Capital LLC bought a new position in shares of Sage Therapeutics in the fourth quarter valued at approximately $57,000. US Bancorp DE boosted its position in shares of Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 2,268 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after buying an additional 2,446 shares in the last quarter. 99.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SAGE shares. Wedbush reaffirmed a "neutral" rating and set a $6.00 price objective on shares of Sage Therapeutics in a report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a report on Friday, April 25th. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Scotiabank cut their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. Finally, StockNews.com raised Sage Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $8.81.

Sage Therapeutics Stock Performance

Sage Therapeutics stock traded down $0.18 during mid-day trading on Friday, reaching $7.30. The company's stock had a trading volume of 1,060,063 shares, compared to its average volume of 1,221,130. The company has a market capitalization of $457.13 million, a P/E ratio of -1.11 and a beta of 0.20. The firm's fifty day moving average price is $7.54 and its two-hundred day moving average price is $6.78. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $14.31.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to analysts' expectations of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business's revenue for the quarter was up 78.0% on a year-over-year basis. During the same period last year, the company posted ($1.80) EPS. On average, research analysts predict that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.